KYMR · Stage, GEX levels and seasonality
Kymera Therapeutics, Inc. Common Stock (KYMR)
Last close $131.73 (+2.82%) on 2026-11-06
No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.
Open the chartWeinstein stage
Stage 2B — Advancing (extended) · 60 weeks in this stage · 30-week average $104.07
Stage 2 (advancing): price holds above a rising 30-week average. The stage Weinstein buys.
What would change it: Stage 3 begins if the 30-week SMA (104.07) stops rising while price works around it, or after 3 straight weekly closes below it.
GEX levels
Call wall, put wall and gamma flip for KYMR are on Signa plans. What GEX levels tell you.
Seasonality
| Month | Average return | Months up | Years |
|---|---|---|---|
| January | +8.2% | 33% | 3 |
| February | +6.28% | 50% | 4 |
| March | -13.36% | 0% | 4 |
| April | +13.46% | 50% | 4 |
| May | -11.24% | 25% | 4 |
| June | +17.52% | 50% | 4 |
| July | +6.5% | 25% | 4 |
| August | +3.11% | 50% | 4 |
| September | -2.24% | 25% | 4 |
| October | +8.83% | 100% | 4 |
| November (this month) | +18.71% | 100% | 3 |
| December | +6.18% | 67% | 3 |
Based on up to 4 years of weekly closes. Past seasonality does not predict future returns.
On Signa plans
The Signa score and Action Card for KYMR, live options flow, dark pool prints, today's GEX levels with vanna and charm, and what 40+ AI agents say about it.
No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.
Questions about KYMR
What Weinstein stage is KYMR in?
KYMR is in Stage 2B — Advancing (extended), for 60 weeks, based on completed weekly bars and its 30-week moving average (104.07).
How has KYMR done in November?
Over the last 3 years, KYMR averaged +18.71% in November and rose in 100% of them. Past seasonality does not predict future returns.
Educational content only, not financial advice. Trading involves substantial risk.